CL2015000375A1 - Pharmaceutical composition in the form of microparticles comprising an inert core and at least a first layer of active ingredient; microparticle formation process; pharmaceutical combination; pharmaceutical kit; use to treat and / or prevent edema, cardiovascular diseases, diabetes, hypertension, among others. - Google Patents
Pharmaceutical composition in the form of microparticles comprising an inert core and at least a first layer of active ingredient; microparticle formation process; pharmaceutical combination; pharmaceutical kit; use to treat and / or prevent edema, cardiovascular diseases, diabetes, hypertension, among others.Info
- Publication number
- CL2015000375A1 CL2015000375A1 CL2015000375A CL2015000375A CL2015000375A1 CL 2015000375 A1 CL2015000375 A1 CL 2015000375A1 CL 2015000375 A CL2015000375 A CL 2015000375A CL 2015000375 A CL2015000375 A CL 2015000375A CL 2015000375 A1 CL2015000375 A1 CL 2015000375A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical
- microparticles
- hypertension
- diabetes
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012009583A MX351059B (en) | 2012-08-17 | 2012-08-17 | Oral pharmaceutical composition in the form of microspheres and preparation method. |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015000375A1 true CL2015000375A1 (en) | 2015-07-10 |
Family
ID=50435594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015000375A CL2015000375A1 (en) | 2012-08-17 | 2015-02-17 | Pharmaceutical composition in the form of microparticles comprising an inert core and at least a first layer of active ingredient; microparticle formation process; pharmaceutical combination; pharmaceutical kit; use to treat and / or prevent edema, cardiovascular diseases, diabetes, hypertension, among others. |
Country Status (8)
Country | Link |
---|---|
CL (1) | CL2015000375A1 (en) |
CO (1) | CO7310526A2 (en) |
CR (1) | CR20150077A (en) |
DO (1) | DOP2015000028A (en) |
GT (1) | GT201500035A (en) |
MX (1) | MX351059B (en) |
PE (1) | PE20150710A1 (en) |
WO (1) | WO2014027334A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2707533C2 (en) | 2013-03-27 | 2019-11-27 | Ф. Хоффманн-Ля Рош Аг | Genetic markers for prediction of susceptibility to therapy |
WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
CN104523710B (en) * | 2014-12-30 | 2018-05-25 | 石药集团欧意药业有限公司 | A kind of bisulfate clopidogrel aspirin Composite Double synusia and preparation method thereof |
KR101710441B1 (en) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | Tablet with improved stability and dissolution |
WO2018150286A1 (en) | 2017-02-17 | 2018-08-23 | Unichem Laboratories Ltd | Pharmaceutical composition of apixaban |
CN106821996A (en) * | 2017-03-01 | 2017-06-13 | 华益药业科技(安徽)有限公司 | Enalapril maleate granule and preparation method thereof |
AU2019255599B2 (en) * | 2018-04-16 | 2024-02-29 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Apixaban formulations |
US20210290543A1 (en) * | 2020-02-19 | 2021-09-23 | Nano Pharmasolutions, Inc. | Therapeutic agent nanoparticles and methods of preparation |
US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
CN113413364A (en) * | 2021-05-31 | 2021-09-21 | 辰欣药业股份有限公司 | Enoxaparin sodium injection and preparation method thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100226990A1 (en) * | 2006-01-27 | 2010-09-09 | The Provost, Fellows And Scholars Of The College O | Method of Producing Porous Microparticles |
MXPA06010972A (en) * | 2006-09-25 | 2009-04-17 | World Trade Imp Export Wtie Ag | Process for stabilizing famotidine. |
WO2008045006A1 (en) * | 2006-10-11 | 2008-04-17 | Fako Ilaclari A. S. | Formulations of candesartan |
MX2007008440A (en) * | 2007-07-11 | 2009-02-18 | Senosiain S A De C V Lab | Combined pharmaceutical composition. |
-
2012
- 2012-08-17 MX MX2012009583A patent/MX351059B/en active IP Right Grant
-
2013
- 2013-08-16 WO PCT/IB2013/056690 patent/WO2014027334A2/en active Application Filing
- 2013-08-16 PE PE2015000210A patent/PE20150710A1/en active IP Right Grant
-
2015
- 2015-02-13 CR CR20150077A patent/CR20150077A/en unknown
- 2015-02-16 GT GT201500035A patent/GT201500035A/en unknown
- 2015-02-16 DO DO2015000028A patent/DOP2015000028A/en unknown
- 2015-02-17 CL CL2015000375A patent/CL2015000375A1/en unknown
- 2015-03-04 CO CO15048826A patent/CO7310526A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014027334A2 (en) | 2014-02-20 |
GT201500035A (en) | 2017-10-24 |
MX351059B (en) | 2017-09-29 |
PE20150710A1 (en) | 2015-05-28 |
MX2012009583A (en) | 2014-02-26 |
CO7310526A2 (en) | 2015-06-30 |
DOP2015000028A (en) | 2015-03-15 |
CR20150077A (en) | 2015-05-13 |
WO2014027334A3 (en) | 2014-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015000375A1 (en) | Pharmaceutical composition in the form of microparticles comprising an inert core and at least a first layer of active ingredient; microparticle formation process; pharmaceutical combination; pharmaceutical kit; use to treat and / or prevent edema, cardiovascular diseases, diabetes, hypertension, among others. | |
CL2013001136A1 (en) | A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent. | |
CL2014002754A1 (en) | Solid controlled release dose form comprising a nucleus with a first portion of an opioid analgesic and a cover that encloses the nucleus and comprises a second portion of the opioid analgesic; Preparation method; use in the treatment of pain. (divisional of application n ° 1450-2014). | |
JP2013540852A5 (en) | ||
CL2013000481A1 (en) | Method and to improve the efficacy and / or reduce the side effects of a suboptimally administered pharmacotherapy comprising the administration of a substituted hexitol; pharmaceutical composition; pharmaceutical combination; Use to treat proliferative diseases. | |
CL2014002283A1 (en) | Solid oral immediate release dosage form comprising particles comprising a core with a first active agent, a coating with a second active agent on it and a pH sensitive material on said coated core; process to prepare it; treatment method; and use to treat pain. | |
CL2014001070A1 (en) | Compounds derived from amino acids functionalized in the n-terminal, capable of forming micro- or nanoparticles to encapsulate an agent; composition; use to treat diseases; and method of delivering a polynucleotide to a cell. | |
CL2013001586A1 (en) | Rapid dispersion microgranular composition comprising at least one sugar alcohol, a saccharide, or a mixture thereof, at least one super disintegrant and at least one multifunctional additive; oral disintegration tablet comprising the microgranular composition and at least one active ingredient; and manufacturing methods. | |
CL2011001091A1 (en) | Solid oral pharmaceutical dosage form comprising at its core nifedipine or nisoldipine and in a mantle coating around the core at least one angiotensin II antagonist and / or at least one diuretic; procedure for its preparation, useful to treat hypertension. | |
CL2012002909A1 (en) | Process for preparing a pharmaceutical composition comprising a) a granulated center consisting of agglomerated active ingredient grains in the presence of binder and b) a coating layer of said granulated center constituted by fatty matrix; pharmaceutical composition; and its use for oral administration | |
CL2013002504A1 (en) | Solid coated pharmaceutical preparation comprising at least one active ingredient and because the coating has a thickness of 0.1 to 100 nm, preferably 0.3 to 50 nm and more preferably 0.5 to 35 nm; and its method of preparation | |
CL2013003143A1 (en) | Use of compounds derived from phenylaminopyrimidinyl, an enantiomer or a pharmaceutically acceptable salt thereof to reduce the viability of multiple myeloma cells in a state of non-responsive cells to il-6 and / or having a cd45- phenotype. | |
CL2014000849A1 (en) | Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases. | |
CL2013002905A1 (en) | Pharmaceutical composition comprising fimasartan, a salt, solvate or hydrate thereof and amlodipine, an isomer, salt, solvate or hydrate thereof; Use in the treatment of hypertension and cardiovascular diseases. | |
CL2013003700A1 (en) | Topical ophthalmological pharmaceutical composition comprising regorafenib, which is suspended in a pharmaceutically acceptable vehicle; manufacturing procedure and its use to treat or prevent an ophthalmological disorder. | |
ECSP13012847A (en) | DIMALEATE OF 9- [4- (3-CHLORINE-2-FLUORO-PHENYLAMINE) -7-METOXI-QUINAZOLIN-6-ILOXI] -1,4-DIAZA-ESPIRO [5.5] UNDECAN-5-ONA, ITS USE AS A MEDICINAL PRODUCT AND HIS PREPARATION. | |
RS54475B1 (en) | New combination | |
CL2014003525A1 (en) | Pharmaceutical composition comprising fimasartan, hydrochlorothiazide and a binder; preparation procedure; its use in the treatment of hypertension. | |
BRPI0915527A2 (en) | pepitides, pharmaceutical composition and exosomes comprising the same, methods and uses | |
CL2015000857A1 (en) | A pharmaceutical composition consisting of a first layer comprising metformin and a second layer comprising gemigliptin; its method of preparation, useful for the prevention and treatment of diabetes. | |
CL2008001043A1 (en) | AMORPHY AND CRYSTALLINE FORM OF THE OXYM OF E-1- (4 - ((1R, 2S, 3R) -1,2,3,4-TETRAHYDROXIBUTIL) -1H-IMIDAZOL-2-IL) -ETANONA; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT, CONTROL OR PREVENT AN ILLNESS OR AN AUTOIMMUNE OR INFLAMMATORY DISORDER. | |
BRPI0920878A2 (en) | ksp161 inhibitor to increase apoptosis, its administration and its use. | |
UY31903A (en) | 7-SULFANILMETIL-, 7-SILFINILMETIL-Y7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME | |
CO6721030A2 (en) | Formulation of a complex comprising lercanidipine hydrochloride and valsartan and method for preparing it | |
HRP20130082A2 (en) | Pharmaceutical composition with sustained release of trimetazidine |